接受度普利尤单抗(一种白细胞介素-4/13抑制剂)治疗的特定性皮炎患者中附着点炎与关节炎性肌肉骨骼综合征的特征分析
本文报告本中心接受度普利尤单抗治疗后出现新发肌肉骨骼症状的观察性队列。2018年10月至2021年2月共470例特定性皮炎患者开始度普利尤单抗治疗,36例转诊风湿科评估,其中26例(14男12女)被鉴定为炎症性附着点炎、关节炎和/或腱鞘炎的肌肉骨骼综合征,临床发现经超声和MRI确认。所有患者对度普利尤单抗治疗反应很好,未发现该综合征的特异性预测因素;症状轻度16例、中度6例、重度4例;使用非甾体抗炎药或环氧化酶2抑制剂、减少度普利尤单抗剂量/频率及停用度普利尤单抗可带来改善,但中度或重度症状持续数月。
要点
- 470例特定性皮炎患者接受度普利尤单抗治疗,36例转诊风湿科,26例出现炎症性附着点炎、关节炎和/或腱鞘炎。
- 所有患者对度普利尤单抗治疗反应很好,未发现该肌肉骨骼综合征的特异性预测因素。
- 症状轻度16例、中度6例、重度4例;非甾体抗炎药或环氧化酶2抑制剂、减量/减频及停药可改善,但中重度症状持续数月。
核心结论
- 作者报告部分接受白细胞介素-4受体拮抗剂度普利尤单抗治疗的患者出现新的炎症性附着点炎/关节炎/腱鞘炎肌肉骨骼综合征。
- 作者认为这一对细胞因子靶向治疗的反应为附着点炎的发病机制提供了关键见解。
研究设计与样本
- 本文报告本中心接受度普利尤单抗治疗后出现新发肌肉骨骼症状患者的观察性队列。
- 所有患者均接受全面风湿病史与检查,多数患者接受超声或磁共振成像检查。
- 2018年10月至2021年2月,从常规临床护理记录中记录470例开始度普利尤单抗治疗的特定性皮炎患者。
主要发现
- 470例开始度普利尤单抗治疗的特定性皮炎患者中,36例转诊风湿科评估。
- 36例转诊患者中鉴定26例(14男、12女)为炎症性附着点炎、关节炎和/或腱鞘炎的肌肉骨骼综合征,临床发现经超声和磁共振成像确认。
- 所有患者对度普利尤单抗治疗反应很好,未发现该肌肉骨骼综合征的特异性预测因素。
- 症状轻度16例、中度6例、重度4例。
- 使用非甾体抗炎药或环氧化酶2抑制剂、减少度普利尤单抗剂量/频率及停用度普利尤单抗治疗带来改善,但中度或重度症状持续数月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the presentation and outcomes of patients with atopic dermatitis (AD) who developed musculoskeletal symptoms after treatment with dupilumab, a human IgG4 monoclonal antibody that blocks the functions of interleukin-4 (IL-4) and IL-13, key pathologic pathways in AD. METHODS: This article reports an observational cohort of patients receiving dupilumab who developed new-onset musculoskeletal symptoms after dupilumab therapy at our center. All patients had a comprehensive rheumatologic history and examination, with imaging by ultrasonography (US) or magnetic resonance imaging (MRI) in most patients. RESULTS: Between October 2018 and February 2021, we recorded 470 patients with AD commencing dupilumab treatment from routine clinical care records. Of 36 patients referred for rheumatologic assessment, we identified 26 patients (14 male, 12 female) with a musculoskeletal syndrome of inflammatory enthesitis, arthritis, and/or tenosynovitis. Clinical findings were confirmed by US and MRI. All patients had very good response to dupilumab treatment, and no specific predictors of musculoskeletal syndrome were noted. Symptoms were mild in 16 patients, moderate in 6 patients, and severe in 4 patients. Receipt of nonsteroidal antiinflammatory drugs or cyclooxygenase 2 inhibitors, reduction of dupilumab dose/frequency, and cessation of dupilumab therapy led to improvement, but moderate or severe symptoms persisted for many months. CONCLUSION: We report a new musculoskeletal syndrome of inflammatory enthesitis/arthritis/tenosynovitis in some patients receiving the IL-4 receptor antagonist dupilumab. This response to a cytokine-targeting therapy provides key insights into the pathogenesis of enthesitis.
引用
- Hughes CD, Nathan J, Mathew L, et al. Characterization of a Musculoskeletal Syndrome of Enthesitis and Arthritis in Patients With Atopic Dermatitis Treated With Dupilumab, an Interleukin-4/13 Inhibitor. Arthritis Rheumatol. 2023. PMID: 37163452. doi:10.1002/art.42558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。